TMCnet News
Research and Markets: Breast Cancer Drug Pipeline Update 2015 - 400 Companies Plus Partners Developing 540 Drugs Targeting Breast Cancer in DevelopmentResearch and Markets (http://www.researchandmarkets.com/research/f27fhc/breast_cancer) has announced the addition of the "Breast Cancer Drug Pipeline Update 2015" report to their offering. Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall survival remains below five years. There are today 400 companies plus partners developing 540 drugs targeting breast cancer in development. In addition, there are 8 suspended dugs and the accumulated number of ceased drugs over the last years amount to another 233 drugs. Breast Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 345 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 330 out of the 334 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 68 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath. Pipeline Breakdown According to Number of Drugs
Delivery Format: Desktop App plus Online Access to Updates (One Year) For more information visit http://www.researchandmarkets.com/research/f27fhc/breast_cancer
|
